Aurobindo Pharma’s wholly owned subsidiary -- Eugia Pharma Specialities has launched Pomalidomide Capsules, 1 mg, 2 mg, 3 mg and 4 mg, in the US market. The product is the generic equivalent of Pomalyst Capsules, 1 mg, 2 mg, 3 mg and 4 mg, of BMS Pharmaceuticals Corp. Eugia Pharma Specialities was one of the First-to-File (FTF) ANDA applicants for this product. The product will be manufactured at Eugia Unit-I.  

According to IQVIA MAT data for the twelve months ending January 2026, Pomalidomide Capsules have an estimated market size of approximately $3.3 billion in the U.S. Pomalidomide is a third-generation immunomodulatory drug (IMiD) used in combination with dexamethasone (and sometimes bortezomib) to treat relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.